Table 1.
Summary of clinical features of the patients infected with SARS-CoV-2
| Patient | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| P1 | P2 | P3 | P4 | P5 | P6 | P7 | P8 | P9 | P10 | |
| Country | Germany | Germany | Germany | Germany | USA | USA | Venezuela | Venezuela | Bolivia | USA |
| Age (years) | 86 | 51 | 50 | 66 | 38 | 45 | 44 | 61 | 32 | 39 |
| Sex | F | M | F | M | F | M | F | F | F | F |
| Relationship | Mother-in-law of P3 | – | Daughter-in-law of P1 | – | Wife of P6 | Husband of P5 | – | – | – | – |
| Occupation | Housewife | Carpenter | Housewife | Retired | Unemployed Colombian veterinarian | Dialysis Hospital cleaning and disinfection company manager | Housewife | Engineer | Government employee | Physician |
| Chronic medical illness | Coronary bypass 13 years ago, breast cancer 24 years ago | None | None | None | None | None | Systemic lupus erythematosus (SLE) | Type 2 diabetes mellitus | None | Adult Still’s disease |
| Symptoms started, date | 18-Mar-20 | 14-Mar-20 | 23-Mar-20 | 23-Mar-20 | 18-Mar-20 | 10-Mar-20 | 11-Apr-20 | 09-Mar-20 | 21-Mar-20 | 7-Apr-20 |
| Interval between symptom onset and consultation (days) | 1 | 2 | 1 | 4 | 2 | 2 | 1 | 2 | 12 | 0 |
| Consultation date | 19-Mar-20 | 16-Mar-20 | 24-Mar-20 | 27-Mar-20 | 20-Mar-20 | 12-Mar-20 | 12-Apr-20 | 11-Mar-20 | 2-Apr-20 | 7-Apr-20 |
| Presenting symptoms and signs | ||||||||||
| Fever | – | – | – | D1 | – | D1 | D2 | D2 | – | D3 |
| Cough | D1 | D1 | D1 | D1 | D1 | D2 | D1 | D1 | – | – |
| Malaise | D1 | – | – | – | D3 | D1 | D1 | D1 | D1 | – |
| Dyspnea | – | D1 | D1 | – | D2 | – | – | D1 | – | – |
| Generalized weakness | – | – | – | – | – | D1 | D1 | D2 | – | D3 |
| Headache | – | – | – | – | D3 | – | D1 | D1 | – | – |
| Diarrhea | – | – | – | – | D3 | D1 | – | – | – | D21 |
| Polyarthralgia | – | – | D5 | – | – | – | D2 | – | – | – |
| Dehydrated | D3 | – | – | – | – | – | – | – | – | – |
| Ageusia | D2–D7, 5 days | D1–D5, 5 days | D5–D7, 22 days | D1–D11, 11 days | D5–D16, 11 days | D4–D29, 25 days | D2–D8, 7 days | D2–D5, 4 days | – | D10–D18, 8 days |
| Anosmia | – | – | D5–D7, 22 days | D1–D11, 11 days | D5–D16, 11 days | D4–D29, 25 days | 2D(POS)–D4 then D7-D14, 13 days | D1–D5, 5 days | D1–D7, 7 days | D7–D15, 8 days |
| Hospitalized | Yes | No | No | Yes | No | No | Yes | No | No | No |
| Discharged at day | 17 | – | – | 15 | – | – | 10 | – | – | – |
| Body temperature (°C) | 36.9 | 37.0 | 37.0 | 39.0 | 37.0 | 37.9 | 37.3 | 37.0 | 37.0 | 38.6 |
| Systolic blood pressure (mmHg) at income | 125 | 105 | 110 | 120 | N/A | N/A | 120 | 110 | N/A | N/A |
| Dyastolic blood pressure (mmHg) at income | 80 | 70 | 70 | 80 | N/A | N/A | 85 | 70 | N/A | N/A |
| Cardiac frequency (bpm) | 91 | 72 | 70 | 60 | N/A | N/A | 81 | 75 | N/A | N/A |
| Oximetry saturation (%) | 98 | N/A | N/A | 92 | N/A | N/A | 97 | 98 | N/A | 93–94 |
| White blood cell count (× 109 cells/L); (normal range 3.9–9.9) | 5.08 | N/A | N/A | 6.75 | N/A | N/A | 5.05 | 6.70 | N/A | N/A |
| Lymphocyte count (× 109 cells/L); (normal range 1.1–3.6) | 508 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Platelet count (× 109 cells/L); (normal range 162–341) | 140 | N/A | N/A | 259 | N/A | N/A | 130 | 140 | N/A | N/A |
| D-dimer (μg/mL) (normal range 0.0–0.5) | 1.48 | N/A | N/A | 0.88 | N/A | N/A | N/A | N/A | N/A | 0.64 |
| Ferritin (ng/mL) (normal range 12–150) | 312 | N/A | N/A | 1288 | N/A | N/A | 240 | 190 | N/A | N/A |
| Fibrinogen (g/dL) (normal range 2.0–4·0) | 370 | N/A | N/A | 1000 | N/A | N/A | N/A | N/A | N/A | N/A |
| C-reactive protein (mg/L) (normal range 0.0–5.0) | 33 | N/A | N/A | 71.2 | N/A | N/A | 43 | 35 | N/A | 55 |
| Aspartate aminotransferase (U/L) (normal range 0.0–32.0) | 53 | N/A | N/A | 230 | N/A | N/A | N/A | N/A | N/A | N/A |
| Potassium (mmol/L) (normal range 3.5–5.1) | 2.8 | N/A | N/A | 4.5 | N/A | N/A | N/A | N/A | N/A | N/A |
| Serum chloride (mmol/L) (normal 98–107) | 95 | N/A | N/A | 96 | N/A | N/A | N/A | N/A | N/A | N/A |
| Lactate dehydrogenase (U/L) (normal range 135–214) | 376 | N/A | N/A | 414 | N/A | N/A | N/A | N/A | N/A | N/A |
| IL-6 (pg/mL) (normal < 7) | 7.3 | N/A | N/A | 29.7 (D5), 49.4 (D6), 14.4 (D10) | N/A | N/A | N/A | N/A | N/A | N/A |
| RT-PCR for Influenza viruses | Negative | N/A | N/A | Negative | N/A | N/A | N/A | N/A | N/A | N/A |
| RT-PCR for SARS-CoV-2 | Positive, D6, D10, D11, D17 | Positive | Positive | Positive | Positive | Positive | Positive, D3 | Positive, D2 | Positive | Positive |
| Antibodies, anti-SARS-CoV-2 (OD ratio) (normal < 8) | ||||||||||
| IgG | 13.93 (D11), 14.54 (D17) | 8.04 (D23) | N/A | 14.74 (D10), 12.17 (D18) | N/A | N/A | N/A | N/A | N/A | N/A |
| IgA | 8.0 (D11), 12.3 (D17) | 8.19 (D23) | N/A | 40.21 (D10), 38.58 (D18) | N/A | N/A | N/A | N/A | N/A | N/A |
Written consent was obtained from all the patients
F female, M male, P1 patient 1, P2 patient 2, P3 patient 3, P4 patient 4, P5 patient 5, P6 patient 6, D day of the disease, – negative, N/A not assessed, IL-6 interleukin 6, RT-PCR reverse-transcriptase polymerase chain reaction, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2, 2D(POS) 2 days before the onset of symptoms